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Abstract
Background: Long noncoding RNAs (lncRNAs) have been suggested to be involved in the development and
progression of malignancies. However, the investigation of small nucleolar RNA host gene 20 (SNHG20) on cancer
progression remains unknown. The present study aims to explore the clinical significance of SNHG20 and its
potential molecular mechanism in colorectal cancer (CRC).
Methods: Quantitative real-time PCR (qRT-PCR) was used to measure the SNHG20 expression in a total of 107 CRC
tissues and CRC cell lines. Loss of function approach was employed to explore the biological roles of SNHG20 in
vitro. Its potential molecular mechanism was further verified by western blotting and qRT-PCR.
Results: The results suggested that SNHG20 expression was significantly upregulated in CRC tissues compared to
corresponding normal tissues from 107 CRC patients. High expression of SNHG20 was remarkably associated with
advanced TNM stage in patients with CRC. Multivariate analyses unraveled that SNHG20 expression was an
independent prognostic factor for overall survival in CRC patients. Further functional assays revealed that
knockdown of SNHG20 suppressed cell proliferation, invasion and migration, and cell cycle progression in CRC
cells. Moreover, SNHG20 regulated cell growth through modulation of a series of cell cycle-associated genes.
Conclusions: Our findings suggest that dysregulation of SNHG20 participates in CRC progression and may serve
as a potential therapeutic target in CRC patients.
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Abbreviation: CRC, Colorectal cancer; EMT, Epithelial to mesenchymal transition; HULC, Hepatocellular carcinoma
upregulated long noncoding RNA; lncRNA, Long noncoding RNA; MALAT1, Metastasis-associated lung
adenocarcinoma transcript 1; OS, Overall survival; ROC, Receiver operating characteristic curve; SNHG20, Small
nucleolar RNA host gene 20
Background
Colorectal cancer (CRC) is the second most common in
females and the third most frequent cancers in males,
with an incidence in Europe of 471000 new cases and
228000 deaths in 2012 worldwide [1]. CRC is becoming
as one of the most common malignancies and the fifth
major cause of cancer-associated deaths in China [2].
Mortality caused by CRC in developed countries is de-
clining, but there is a rapidly rising trend in China [3].
Despite improvements achieved in surgical resection and
adjuvant chemotherapies, the 5-year survival rate of
CRC patients remains unsatisfied [4]. Moreover, the 5-
year survival rate of patients with resectable colorectal
liver metastases is > 40 % but < 10 % in those with unre-
sectable colorectal liver metastases [5]. Local and sys-
temic metastases are the major causes for unsatisfactory
outcomes of CRC patients. Currently, no widely
approval parameter is used to offer a reliable informa-
tion for clinical outcomes of patients with CRC [6].
Therefore, identification of effective carcinogenesis-
associated molecular biomarkers that significantly un-
ravel the clinical characteristics and implications of CRC
is an important purpose of CRC investigation.
It is well known that long noncoding RNA (lncRNA)
is transcribed RNA molecules more than 200 nucleo-
tides and lack protein-coding potential [7]. LncRNAs are
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frequently presented as a disease-, tissue-, or stage-
specific manner [8]. Multiple lines of evidence have indi-
cated that lncRNAs, functioning as oncogenes or tumor
suppressors, play important roles in the modulation of
cellular processes, such as differentiation, proliferation,
and metastasis [9]. Several specific lncRNAs have been
increasingly considered as diagnostic or prognostic cancer
biomarkers, including in CRC [10–12]. For example,
metastasis-associated lung adenocarcinoma transcript 1
(MALAT1), a well-known lncRNA, is markedly overex-
pressed in CRC and has been suggested as a diagnostic
cancer indicator [13–15]. Another characterized lncRNA,
Hox transcript antisense intergenic RNA (HOTAIR), is
also overexpressed in colorectal cancer, combines with
PRC2 (Polycomb Repressive Complex 2) and changes the
regulation of genes, leading to aberrant histone H3K27
methylation and further facilitating cancer progression
and metastasis [11, 16, 17]. However, for all we know, the
involvement of lncRNAs in CRC disease and prognosis is
just starting to be investigated.
Small nucleolar RNA host gene 20 (SNHG20, Gen-
Bank Accession ID NR_027058.1) localized at 17q25.2 is
originally identified in hepatocellular carcinoma (HCC)
and suggested to be overexpressed in 2 HCC cohorts
and TGCA dataset [18]. Moreover, SNHG20 expression
may serve as a useful prognostic factor for patients with
HCC [18]. However, its potential prognostic value and
biological function in CRC have not yet been explored.
In our current study, we first identified that SNHG20
overexpression was associated with aggressive phenotypes
of CRC and worse outcomes in CRC patients. Further
function experiments in vitro suggested that suppression
of SNHG20 blocked cell proliferation, migration, invasion
and cell cycle progression. Moreover, knockdown of
SNHG20 affected the expression of cell cycle-associated
genes in CRC cells. Taken together, these data suggest that




All aspects of this study were approved by the Ethics Board
of First Hospital Affiliated to Anhui Medical University. The
written informed consents were obtained from all enrolled
patients, and all relevant investigations were performed ac-
cording to the principles of the declaration of Helsinki.
A total of 107 CRC paired tissue specimens (tumor and
non-tumor tissues) were collected and histologically con-
firmed by a pathologist at The People’s Hospital of Chizhou
or First Hospital Affiliated to Anhui Medical University,
from January 2006 to January 2011. Corresponding normal
tissues were taken 5–10 cm away from the edge of the
tumor and contained no obvious tumor cells by the path-
ologist. Tissue specimens were immediately kept in RNA
keeper tissue stabilizer (Vazyme, Nanjing, China) after sur-
gery and then stored in −80 °C until RNA extraction. None
of patients received anti-cancer treatment before surgery.
Other types of cancers were not observed before operation.
The detailed information on clinical characteristics of CRC
patients in the present study is shown in Table 1. We also
performed a follow-up study including physical examin-
ation, laboratory analysis, and colonoscopy if necessary.
Cell culture
Human normal intestinal epithelial cell line FHC and
CRC cell lines HCT8, HT29, HCT116, SW480, LOVO
were purchased from a cell bank at Chinese Academy of
Table 1 Correlation between the clinicopathological factors and
expression of SNHG20
Factors Tumor low expression
(n = 53) N (%)
Tumor high expression
(n = 54) N (%)
Pa
Sex
Male 37 (69.8) 38 (70.4) 0.949
Female 16 (30.2) 16 (29.6)
Age (years)
< 65 25 (47.2) 26 (48.1) 0.919
≥ 65 28 (52.8) 28 (51.9)
Tumor location
Colon 32 (60.4) 42 (77.8) 0.051
Rectum 21 (39.6) 12 (22.2)
TNM
I-II 30 (56.6) 20 (37.0) 0.043
III-IV 23 (43.4) 34 (63.0)
T
T1-T2 11 (20.8) 3 (5.6) 0.020
T3-T4 42 (79.2) 51 (94.4)
N
N0 30 (56.6) 30 (55.6) 0.913
N1-N2 23 (43.4) 24 (44.4)
M
M0 44 (83.0) 32 (59.3) 0.007
M1 9 (17.0) 22 (40.7)
Gradeb
G1-G2 46 (86.8) 40 (74.1) 0.098
G3 7 (13.2) 14 (25.9)
CEA
< 5 ng/mL 19 (35.8) 8 (14.8) 0.012
≥ 5 ng/mL 34 (64.2) 46 (85.2)
Statistical significance is highlighted by bold font
T depth of tumor, N lymph node, M distant metastasis, CEA
carcino-embryonic antigen
aTwo-sided chi-square test
bGrade 1 and 2 stand for high or middle differentiated tumor, grade 3 stands
for poorly differentiated tumor
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Sciences (Shanghai, China). All cell lines were cultured
in RPMI 1640 medium (Gibco, MD, USA) contained
10 % fetal bovine serum (HyClone, Logan, USA) and 100
U/ml streptomycin/penicillin (Gibco, MD, USA). The
cells were maintained in a humidified atmosphere con-
taining 5 % CO2 at 37 °C.
RNA isolation and quantitative real-time PCR
Total RNA was extracted from CRC tissues with TRIzol re-
agent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocols. The cDNA was synthesized from
1 μg of total RNA in a final volume of 20 μl using a Prime-
Script RT reagent Kit with gDNA Eraser (Takara, Dalian,
China). Its synthesis was conducted at 37 °C for 15 min,
then 85 °C for 5 s according to the experimental protocols.
Quantitative real-time PCR (qRT-PCR) was performed
using a SYBR Premix EX Taq™ Kit (Takara, Dalian, China)
by an ABI 7500 Real-Time PCR system (Applied Biosys-
tems, Foster City, USA). GAPDH was employed as an in-
ternal control. Primer sequences of SNHG20: F, 5′-
ATGGCTATAAATAGATACACGC-3′ and R, 5′-GGTA-
CAAACAGGGAGGGA-3′; p21: F, 5′-CAGAGGAGGCG
CCATGT-3′, R, 5′-GGAAGGTAGAGCTTGGGCAG-3′;
CCNA1: F, 5′-ATTCATTAAGTGAAATTGTGC-3′ and
5′-CTTCCATTCAGAAACTTATTG-3′. GAPDH: F, 5′-A
CAGTCAGCCGCATCTTCT-3′ and R, 5′-GACAAGC
TTCCCGTTCTCAG-3′. The reaction was conducted in a
reaction volume of 20 μl as the following processes: initial
denaturation at 95 °C for 30 s, followed by 40 cycles for
95 °C for 5 s, 60 °Cfor 30 s. Fold changes were calculated
using a relative quantification (2-ΔΔCt).
RNA interference
For knockdown of SNHG20 expression, small interfering
RNAs that targeted SNHG20 (si-SNHG20-1, si-SNHG20-2)
and a scrambled negative control (si-NC) were purchased
from Shanghai GenePharma Co. (Shanghai, China). The se-
quences of siRNAs (si-SNHG20-1, 5′-GCCUAGGAU-
CAUCCAGGUUTT-3′; si-SNHG20-2, 5′-GCCACUCAC
AAGAGUGUAUTT-3′) and si-NC were chemically synthe-
sized and transfected into LOVO/SW480. Briefly, a total of
1.0 × 105 cells were seeded in 6-cm culture dishes overnight
and subsequently transfected with siRNAs described above
by the Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for
48 h. Transfected cells were then subjected into further
functional assays and RNA/protein extraction.
Cell proliferation assay
2-(2-Methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-dis-
ulfothenyl)-2H-tetrazolium salt (CCK-8, Dojindo, Rock-
ville, USA) assay was performed to assess cell viability
according to the manufacturer’s instruction. Briefly, trans-
fected cells were seeded in 96-well plates (1.0 × 103/per
well). CCK-8 solution was added to each well, and cells
were maintained for 1 h. The absorbance of each well was
measured at 450 nm by a microplate reader victor
(Enspire 2300 Maltilabel Reader, PerkinElmer, Singapore).
Cell apoptosis assay
Cell apoptosis was analyzed using flow cytometry after
staining with propidium iodide (PI) and Annexin V-
FITC (BD Bioscience, CA, USA). Cells were transfected
with si-NC or si-SNHG20-1 in 6-well plate. Cell apop-
tosis was then analyzed after 48-h transfection. Cell
apoptosis assays were conducted in triplicate.
Flow cytometric analysis
Transfected cells (5 × 105) were fixed with 70 % ethanol
and resuspended in 0.5 mL PBS, and then added with
propidium iodide and 1 μg/mL RNase for 30 min. Proc-
essed samples were analyzed with a Beckman Coulter
FC500 (Beckman Coulter, CA, USA). The experiments
were performed in triple.
Cell migration and invasion assays
For migration, transfected cells (1 × 104) were plated into
the upper chamber (BD Biosciences, San Jose, USA). For
invasion, transfected cells (1 × 104) were added to the
upper chamber coated with matrigel (Millipore, Billerica,
USA). RPMI-1640 containing 20 % FBS was plated into
the lower chamber as a chemoattractant. After 24-h cul-
ture, membranes of the upper chamber were stained
with 0.1 % crystal violet for 15 min. Migrated or invaded
cells on the lower membrane were calculated under a
light microscope (Olympus, Tokyo, Japan).
Western blot analysis
Cellular protein lysates were isolated in a 10 % SDS-
polyacrylamide gel and then transferred onto the polyvinyli-
dene fluoride (PVDF) membranes (Bio-Rad, Hercules,
USA). Membranes were blocked with 5 % non-fat dried
milk containing antibody to p21 (Cell Signaling Technol-
ogy, MA, USA, 1:1000), CyclinA1 (Abcam Biotechnology,
USA, 1:1000) or GAPDH (Santa Cruz Biotechnology, CA,
USA, 1:900) overnight at 4 °C. The membranes were then
incubated with horseradish peroxidaselinked secondary
antibody after washing with PBST. The proteins were visu-
alized using ECL chemiluminescence. Bands were analyzed
with Image J (National Institutes of Health, MD, USA).
Statistical analysis
All experiments were independently repeated in triple.
Data were expressed as mean ± standard deviation (SD)
or frequencies and percentages if necessary. The χ2 test
and Mann–Whitney U-test were used to investigate dif-
ferences among groups of patients with low or high
SNHG20 expression levels. The data from in vitro func-
tional assays were analyzed by One-way ANOVA or
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Dunnett’s post-hoc test for multiple comparisons. Pre-
dictive value of SNHG20 was evaluated by the receiver
operating characteristic curve (ROC) analysis. Kaplan-
Meier method and log-rank test were used to assess the
probability of overall survival (OS). Survival data were
further estimated using the univariate and multivariate
Cox proportional hazards model. Significant variables in
univariate analyses were used in multivariate analyses ac-
cording to the Cox regression analyses. P < 0.05 was
chosen for statistical significance.
Results
LncRNA SNHG20 is up-regulated in human CRC tissues
and cell lines
To know the expression manner of SNHG20, we mea-
sured the expression of SNHG20 in 107 pairs of CRC
and corresponding normal tissues by qRT-PCR. The re-
sults indicated that SNHG20 expression in tumor tissues
was markedly higher than that in adjacent non-tumor
tissues (P < 0.001, Fig. 1a). To further confirm its expres-
sion levels in CRC, we measured the levels of SNHG20
expression in FHC and CRC cell lines (HCT8, HT29,
HCT116, SW480, and LOVO). We observed that CRC
cell lines exhibited higher levels of SNHG20 compared
with FHC cells (P < 0.05, Fig. 1b).
Association between SNHG20 and clinicopathological
features of CRC
To further understand the clinical significance of
SNHG20 up-regulation in CRC patients, we carried out
to identify potential correlations between SNHG20 ex-
pression and clinical characteristics of CRC. The main
characteristics of 107 CRC patients are summarized in
Table 1. Furthermore, the optimal cutoff value of
SNHG20 expression was 2.86-fold for OS with the lar-
gest Youden’s index according to the relative expression
levels of SNHG20 (Fig. 2a). All CRC patients were sub-
sequently divided into two groups (high expression
group ≥ 2.86 and low expression group < 2.86). The de-
tailed relationships between SNHG20 expression manner
and clinicopathological features of CRC patients are
shown in Table 1. Interestingly, SNHG20 overexpression
in CRC patients had a significant association with ad-
vanced TNM stage (P = 0.043), depth of invasion (P =
0.020), distant metastasis (P = 0.007), and CEA (P = 0.012).
High expression of SNHG20 is correlated with poor
prognosis of patients with CRC
Subsequently, survival analyses were conducted to assess
the association between SNHG20 expression and overall
survival of CRC patients by Kaplan-Meier survival
curves and log-rank test. The results showed that the ex-
pression levels of SNHG20 were reversely associated
with OS (P < 0.001, Fig. 2b). Furthermore, Cox regres-
sion analyses were conducted to evaluate the prognostic
factors in 107 CRC patients. Univariate analysis showed
that patients with depth of invasion (P = 0.040), distant
metastasis (P < 0.001), tumor differentiation (P = 0.039),
and high SNHG20 (P < 0.001) expression had markedly
shorter overall survival (Table 2). Multivariate analysis
further indicated that SNHG20 expression was a signifi-
cant independent prognostic factor for CRC patients
(HR = 2.97, 95 % CI = 1.51–5.82, P = 0.002). Addition-
ally, SNHG20 expression also served as an independent
indicator for non-metastatic patients with CRC in
Fig. 1 Relative SNHG20 expression in human CRC tissues and cell lines. a The expression of SNHG20 was measured by qRT-PCR in tumor and
non-tumor tissues from 107 paired CRC samples. SNHG20 expression levels were normalized to GAPDH. b Relative expression of SNHG20 between
five CRC cell lines (HCT8, HT29, HCT116, SW480, LOVO) and a normal intestinal epithelial cell line FHC. Each cell line was duplication analyzed
three times. *P < 0.05, ***P < 0.001
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multivariate analysis (HR = 1.63, 95%CI = 1.22-3.98, P =
0.011, Table 3).
Manipulation of SNHG20 expression levels in CRC cells
To assess the biological roles of SNHG20 in CRC, we
examined the levels of SNHG20 expression in a variety
of cells lines, and found that there were higher expres-
sion levels of SNHG20 in LOVO and SW480 cells.
Therefore, we suppressed the endogenous expression of
SNHG20 in LOVO and SW480 cells by siRNA to further
explore the biological effects of SNHG20 on CRC cells.
Two specific siRNAs of SNHG20 were synthesized and
transfected into LOVO and SW480 cells. As shown in
Fig. 3, si-SNHG20-1 effectively inhibited the expression
of SNHG20 (P < 0.001). So, si-SNHG20-1 was selected
for further study.
Knockdown of SNHG20 affects biological behaviors of
CRC cells
To explore whether endogenous knockdown of SNHG20
inhibited proliferative capacity in CRC cells, CCK8 assay
was performed. Growth curves determined by CCK8 as-
says revealed that cell proliferation was dramatically de-
creased by inhibition of SNHG20 expression in LOVO
(Fig. 4a) and SW480 cells (Fig. 4b). To further probe po-
tential mechanisms by which knockdown of SNHG20 at-
tenuated CRC cell proliferation, we estimated cell cycle
in CRC cell lines after SNHG20 knockdown by flow cy-
tometric cell cycle assay. The results showed that
SNHG20 knockdown led to a remarkable accumulation
of CRC cells at G0/G1 phase and a significant reduction
of cells at S + G2/M phase (P < 0.05, Fig. 4c). However,
the proportion of apoptotic cells showed no significant
difference among these groups (P > 0.05, Fig. 4b).
Fig. 2 ROC curve analysis and prognostic significance of SNHG20 in CRC patients. a Receiver operating characteristic (ROC) curve analysis was
used to determine whether SNHG20 is really a good candidate to discriminate tumor tissues from non-tumor tissues. b Kaplan–Meier survival
curve analysis shows that patients with higher expression of SNHG20 had a shorter overall survival compared with those with lower expression of
SNHG20. P value was assessed by log-rank test
Table 2 Summary of overall survival analyses by univariate and multivariate COX regression analyses
Risk factors Univariate analysis Multivariate analysis
HR (95 % CI) P HR (95 % CI) P
Sex 1.17 (0.61–2.24) 0.637
Age (years) 0.92 (0.51–1.66) 0.774
Tumor location 0.95 (0.51–1.77) 0.872
T 8.01 (1.10–58.19) 0.040 4.04 (0.54–30.24) 0.174
N 1.62 (0.89–2.93) 0.114
M 3.51 (1.93–6.37) <0.001 2.83 (1.54–5.20) 0.001
Grade 2.02 (1.04–3.92) 0.039 0.99 (0.46–2.15) 0.981
CEA 1.75 (0.82–3.77) 0.152
SNHG20 (high/low) 3.52 (1.81–6.85) <0.001 2.97 (1.51–5.82) 0cp002
Statistical significance is highlighted by bold font
T depth of tumor, N lymph node, M distant metastasis, CEA carcino-embryonic antigen, HR hazard ratio, CI confidence, interval
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Collectively, SNHG20-induced acceleration of CRC cells
proliferation appeared to be mediated through modula-
tion of cell cycle arrest, rather than apoptosis.
We also observed the impact of SNHG20 knockdown
on CRC cells migration or invasion by Transwell assay.
Our results showed that the SNHG20 knockdown sup-
pressed cell migration by 53.7 % in LOVO cells, and by
55.1 % in SW480, respectively (P < 0.001, Fig. 4d). Matri-
gel invasion assays also illustrated that silence of
SNHG20 in CRC cells caused a significant decrease in
cell invasion (P < 0.001, Fig. 4e). These results revealed
that SNHG20 affected cell migration and invasion in
vitro.
SNHG20 exerts its effect through cell cycle-associated
proteins for promotion of cell cycle progression
As SNHG20 affected cells proliferation through modulation
of the G1-S checkpoint, we examined cell cycle-regulatory
gene expressions at the transcriptional and translational
levels. The results showed that p21 mRNA and protein
levels were significantly increased in CRC cells that were
transfected with si-SNHG20-1 compared to those
transfected with si-NC (Fig. 5a -c). Furthermore, si-
SNHG20-1 attenuated CyclinA1 expression in both LOVO
and SW480 cells (Fig. 5a - c). Taken together, our data sug-
gest that SNHG20 promotes cell proliferation via the accel-
eration of the cell cycle progression.
Discussion
Up to now, this is the first study about the roles of
SNHG20 in human colorectal cancer. In the present
study, we explored its clinical performance in patients
with CRC. We observed that SNHG20 expression was
upregulated in CRC tissues compared to corresponding
normal tissues from 107 CRC patients. Our results
showed that SNHG20 expression was correlated with
TNM stage and serum CEA. In addition, high levels of
SNHG20 expression were associated with worse OS and
could be an independent prognostic indicator for CRC
patients. Interestingly, knockdown of SNHG20 signifi-
cantly suppressed cell proliferation, migration, invasion
and cell cycle progression in vitro in CRC cells. Collect-
ively, SNHG20 may act as an oncogenic function to be
involved in carcinogenesis and development of CRC.
It has been confirmed that ectopic expression of
lncRNAs has the capability to impact cellular functions
through executing as signals, decoys, guides, and scaf-
folds [19, 20]. Furthermore, abnormal lncRNA function
abolishes primary cell biology by inducing epigenetic de-
pressions of downstream target genes [11]. For example,
lncRNA H19 regulated Vimentin, ZEB1, and ZEB2 ex-
pression by competing with endogenous RNA (miR-138
and miR-200a), which resulted in the epithelial to mes-
enchymal transition (EMT) progression [21]. FEZF1-
AS1, a long noncoding RNA upregulated in CRC, accel-
erated malignant development through FEZF1 induction
[12]. Furthermore, accumulating evidence identified that
lncRNA can serve as diagnostic and prognostic markers
for a variety of cancer types including CRC [22, 23]. 91H
expression in CRC may serve as a useful predictor for
overall survival in patients with CRC [10]. A previous
Table 3 Summary of overall survival analyses by univariate and
multivariate COX regression analyses in non-metastatic patients
Risk factors Univariate analysis Multivariate analysis
HR (95 % CI) P HR (95 % CI) P
Sex 1.52 (0.56–4.09) 0.409
Age (years) 0.34 (0.13–0.86) 0.023 0.42 (0.15–1.23) 0.113
Tumor location 1.50 (0.66–3.41) 0.330
T 5.54 (1.05–41.11) 0.034 5.45 (0.68–43.51) 0.109
N 1.79 (0.79–4.08) 0.162
Grade 1.44 (0.34–6.16) 0.623
CEA 1.08 (0.45–2.64) 0.861
SNHG20 (high/low) 2.32 (1.11–5.36) 0.019 1.63 (1.22–3.98) 0.011
Statistical significance is highlighted by bold font
T depth of tumor, N lymph node, CEA carcino-embryonic antigen, HR hazard
ratio, CI confidence, interval
Fig. 3 Manipulation of SNHG20 in CRC cells. QRT-PCR analyses of SNHG20 expression levels after transfection in LOVO (a) and SW480 (b) cells
with si-SNHG20 or si-NC (negative control). **P < 0.01, ***P < 0.001
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study has reported that SNHG20 overexpression in HCC
patients, served as an independent prognostic predictor
for patients with HCC [18]. All these results suggest that
lncRNAs may be involved in the carcinogenesis and pro-
gression of CRC, which encourage us to investigate that
SNHG20 may facilitate CRC malignant progression and
serve as a novel diagnostic or therapeutic target for CRC.
Herein, we have identified that SNHG20 levels were over-
expressed in CRC and may be considered as a predictor for
CRC patients, which were consistent with the previous
findings in HCC [18]. To further explore its biological roles
in CRC, we determined the effect of SNHG20 on CRC cell
biology. CRC cell lines LOVO and SW480 with highest
SNHG20 expression were chosen to explore the influence
of SNHG20 on CRC cell phenotype. Inhibition of SNHG20
in LOVO and SW480 cells led to a significant suppression
of proliferation, migration and invasion as well as cell cycle
arrest. However, the impact of SNHG20 knockdown on the
apoptosis of CRC cells was not observed. These results in-
dicated that knockdown of SNHG20 inhibits cell growth
through blocking cell cycle progression in CRC cells.
Therefore, SNHG20 may represent a promising target for
CRC therapy.
To understand the potential molecular mechanisms by
which SNHG20 promotes proliferation, migration and
invasion of CRC, we assessed its potential target proteins
involved in cell cycle progression. Here, loss of SNHG20
in CRC cells resulted in a marked decrease in Cyclin A1
mRNA and protein expression levels, while SNHG20 ex-
pression was inversely correlated with p21 expression.
Cyclin A1 is a protein that is encoded by the CCNA1
gene belonging to the highly conserved cyclin family in
humans [24], which is shown to bind to some important
cell cycle regulators, such as transcription factor E2F1,
Fig. 4 Influence of SNHG20 knockdown on CRC cells. a At 48 h after transfection, CCK8 assay was performed to determine the proliferation of
LOVO and SW480 cells. b Cell apoptosis was analyzed via flow cytometry after 48-h transfection. c Cell cycle analysis of CRC cells transfected with
si-NC or si-SNHG20. d-e Transwell assays were employed to assess the changes in migratory and invasive capabilities of CRC cells transfected with
si-NC or si-SNHG20. The data are expressed as the mean ± SD. The assays are performed in triple. *P < 0.05, **P < 0.01, ***P < 0.001
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Rb family proteins, and the Kip/Cip family of CDK-
inhibitor proteins [25]. Mounting evidence showed that
Cyclin A1 alters cell cycle progression to induce carcino-
genesis [26, 27]. p21, encoded by the CDKN1A gene lo-
cated on 6p21.2 in humans, is a cyclin-dependent kinase
inhibitor that inhibits the complexes of CDK2 and
CDK1 to mediate the p53-dependent cell cycle G1 phase
arrest [28–30]. Our results indicated that SNHG20 con-
tributes to the proliferation of CRC cells via regulating
Cyclin A1 and p21 expression. However, the precise mo-
lecular regulating how SNHG20 controls Cyclin A1 and
p21 expression remains unclear and requires further
investigation.
Several limitations should be acknowledged in the
present study. Firstly, all samples were only collected
from two hospitals, and the sample size was limited. Fur-
ther studies should be needed to validate the correla-
tions of SNHG20 expression with CRC. Secondly, this
study was a retrospective analysis, which resulted in an-
other limitation. These limitations will claim for a larger,
prospective, randomized and multicenter study in the
future. Additionally, our results did not validate how
SNHG20 regulated cell cycle-associated proteins. So,
further studies are necessary to elucidate the precise
mechanisms by which SNHG20 modulates its targets.
Conclusions
Our present work has demonstrated that SNHG20 ex-
pression is significantly upregulated in CRC tissues, sug-
gesting that SNHG20 may be an adverse prognostic
marker for CRC patients and a higher risk for cancer de-
velopment. The present study showed that SNHG20
may regulate the ability of cell proliferation, invasion
and migration through modulation of Cyclin A1 and
p21 expression. Further insights into the clinical and
functional implications of SNHG20 and its regulated
pathways may facilitate the identification of new diag-




Fig. 5 SNHG20 facilitates CRC cell growth by regulating cell cycle-associated genes and accelerating cell cycle progression. a-b mRNA expression levels
of cell cycle-associated genes in CRC cells transfected with si-SNHG20 or si-NC cells for 48 h. c Protein expression levels of cell cycle-associated genes
in CRC cells transfected with si-SNHG20 or si-NC cells for 48 h. The data are presented as the mean ± SD. All results are representative of three independent
experiments. *P< 0.05, ***P< 0.001
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